---
title: "GLP-1 Receptor Agonist Initiation and Clinically Recorded Alzheimer’s-Type Dementia Risk in Older"
id: "medrxiv-6-glucagon-like-peptide-1-receptor-agonist-initiation-and-risk-of-clinically"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-6-glucagon-like-peptide-1-receptor-agonist-initiation-and-risk-of-clinically"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.21.26361012v1?rss=1"
published_at: "2026-08-24T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GLP-1 Receptor Agonist Initiation and Clinically Recorded Alzheimer’s-Type Dementia Risk in Older
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-6-glucagon-like-peptide-1-receptor-agonist-initiation-and-risk-of-clinically
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.21.26361012v1?rss=1)
- **Published At:** 2026-08-24T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study emulated target trials using the All of Us electronic health record dataset to compare initiation of **GLP-1 receptor agonists** with sulfonylureas (SU) and with **SGLT2 inhibitors** in adults aged ≥55 years with type 2 diabetes, a 12-month washout, and no prior dementia. - Analytical approach combined propensity score weighting, doubly robust estimation, and causal survival forests to estimate individualized treatment effects on 48-month restricted mean survival time (RMST) free from clinically recorded **Alzheimer’s disease (AD)-type dementia**. - In the GLP-1 versus SU comparison (6,328 individuals), initiation of GLP-1 receptor agonists was associated with a small but statistically significant average increase in dementia-free survival: ATE 0.21 months (95% CI: 0.07–0.35); estimated 48-month NNT approximately 202. The top-benefit subgroup gained 0.45 months (95% CI: 0.28–0.62). - In the GLP-1 versus SGLT2 inhibitor comparison (3,070 individuals), the average treatment effect was not statistically significant: ATE 0.06 months (95% CI: –0.18 to 0.31); estimated 48-month NNT approximately 245. However, treatment effects were heterogeneous with a highest-benefit stratum gaining 0.83 months (95% CI: 0.49–1.17). - Predicted greater benefit from GLP-1 initiation was associated with older age, concurrent insulin use, lower HbA1c, and lower BMI according to the heterogeneity analyses. - Authors emphasize these are hypothesis-generating findings and recommend that diabetes treatment choice continue to be guided by glycemic, cardiovascular, renal, and patient-centered considerations. - Data source and access: individual-level data from NIH All of Us Research Program Controlled Tier Dataset v8 (data cutoff Oct 1, 2023); aggregate results are reported in the manuscript and appendix. Access to participant-level data requires authorized researcher credentials and approvals. - Funding was provided by the German Federal Ministry of Research, Technology and Space (03LWH0181B). The All of Us IRB determined the controlled-tier activities did not constitute research involving human subjects requiring individual project review; participants provided informed consent. The authors declared no competing interests.
## Clinical Analysis & Structured Key Points
Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning | medRxiv Skip to main content Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning Jonas Schroeder , Octavia-Andreea Ciora , Philip Heesen , Martin Bendszus , Johannes Levin , View ORCID Profile Robert Perneczky , Lia Bally , Stefan Feuerriegel doi: https://doi.org/10.64898/2026.08.21.26361012 Jonas Schroeder 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: jonas.schroeder{at}lmu.de Octavia-Andreea Ciora 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Philip Heesen 2 Heidelberg University Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Martin Bendszus 3 University Hospital Heidelberg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Johannes Levin 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Robert Perneczky 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Robert Perneczky Lia Bally 4 University of Bern Find this author on Google Scholar Find this author on PubMed Search for this author on this site Stefan Feuerriegel 1 LMU Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors are increasingly used for type 2 diabetes. Despite established metabolic, cardiovascular, and renal benefits, it remains uncertain whether GLP-1 receptor agonists are associated with longer clinically recorded Alzheimer's disease (AD)-type dementia-free survival than sulfonylureas (SU) or SGLT2 inhibitors. Methods Using All of Us electronic health records, we emulated target trials among adults aged 55 years or older with type 2 diabetes, a 12-month washout, and no prior dementia. We compared GLP-1 receptor agonists with SU and SGLT2 inhibitors. Propensity score weighting and doubly robust estimation addressed confounding. Causal survival forests estimated individualized treatment effects on 48-month RMST free from clinically recorded AD-type dementia. Findings In the GLP-1 receptor agonist versus SU comparison (6,328 individuals; 48-month NNT approximately 202), initiation was associated with a small but statistically significant increase in AD-type dementia-free survival (ATE 0.21 months; 95% CI: 0.07-0.35). The highest-benefit stratum gained 0.45 months (95% CI: 0.28-0.62). In the SGLT2 inhibitor comparison (3,070 individuals; 48-month NNT approximately 245), the average effect was not statistically significant (ATE 0.06 months; 95% CI: -0.18 to 0.31), but treatment effects were heterogeneous. The highest-benefit stratum gained 0.83 months (95% CI: 0.49-1.17). Predicted benefit was associated with older age, insulin use, lower HbA1c, and lower BMI. Interpretation GLP-1 receptor agonists may delay clinically recorded AD-type dementia compared with SU. Comparative effectiveness versus SGLT2 inhibitors may vary, supporting further study. Given the hypothesis-generating nature of these findings, diabetes treatment selection should remain guided by glycemic, cardiovascular, renal, and patient-centered considerations. Funding German Federal Ministry of Research, Technology and Space (03LWH0181B) Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The All of Us Institutional Review Board of the National Institutes of Health All of Us Research Program waived ethical approval for this work. The Board determined that activities using Controlled Tier data do not constitute research involving human subjects under 45 CFR 46 and therefore do not require individual project review or approval (All of Us IRB Protocol 2021-02-TN-001; determination dated March 17, 2021, revised August 31, 2021). All participants provided informed consent for participation in the All of Us Research Program. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The individual-level data analysed in this study were obtained from the NIH All of Us Research Program Controlled Tier Dataset v8 (data cutoff Oct 1, 2023) and are available to authorised researchers only through the secure Researcher Workbench (https://workbench.researchallofus.org/). Access requires an institutional Data Use and Registration Agreement, researcher registration and identity verification, completion of the required training, and acceptance of the Data User Code of Conduct. The authors are not permitted to download, redistribute, or provide the participant-level data or the study-specific analytic dataset. Eligible researchers can apply for access at https://www.researchallofus.org/register/. All aggregate data supporting the findings are contained in the manuscript and its appendix. https://workbench.researchallofus.org/ Funder Information Declared German Federal Ministry of Research, Technology and Space , 03LWH0181B Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 24, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning Jonas Schroeder , Octavia-Andreea Ciora , Philip Heesen , Martin Bendszus , Johannes Levin , Robert Perneczky , Lia Bally , Stefan Feuerriegel medRxiv 2026.08.21.26361012; doi: https://doi.org/10.64898/2026.08.21.26361012 Share This Article: Copy Citation Tools Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learning Jonas Schroeder , Octavia-Andreea Ciora , Philip Heesen , Martin Bendszus , Johannes Levin , Robert Perneczky , Lia Bally , Stefan Feuerriegel medRxiv 2026.08.21.26361012; doi: https://doi.org/10.64898/2026.08.21.26361012 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (611) Allergy and Immunology (891) Anesthesia (324) Cardiovascular Medicine (4741) Dentistry and Oral Medicine (473) Dermatology (405) Emergency Medicine (638) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1608) Epidemiology (15778) Forensic Medicine (32) Gastroenterology (1193) Genetic and Genomic Medicine (6947) Geriatric Medicine (724) Health Economics (1049) Health Informatics (4945) Health Policy (1419) Health Systems and Quality Improvement (1729) Hematology (576) HIV/AIDS (1326) Infectious Diseases (except HIV/AIDS) (16223) Intensive Care and Critical Care Medicine (1156) Medical Education (658) Medical Ethics (150) Nephrology (716) Neurology (7139) Nursing (359) Nutrition (1070) Obstetrics and Gynecology (1219) Occupational and Environmental Health (995) Oncology (3560) Ophthalmology (1031) Orthopedics (387) Otolaryngology (442) Pain Medicine (464) Palliative Medicine (138) Pathology (702) Pediatrics (1767) Pharmacology and Therapeutics (730) Primary Care Research (757) Psychiatry and Clinical Psychology (5804) Public and Global Health (9651) Radiology and Imaging (2365) Rehabilitation Medicine and Physical Therapy (1421) Respiratory Medicine (1235) Rheumatology (631) Sexual and Reproductive Health (762) Sports Medicine (571) Surgery (757) Toxicology (106) Transplantation (300) Urology (285)
## Related Clinical Research

- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [GLP-1 receptor agonists and reduced dementia risk in patients with CKD and type 2 diabetes](https://medichelpline.com/clinical-feed/pubmed-41697144.md) (DOI: 10.1093/ndt/gfag032)
- [Antidiabetic Regimens and Risk of Cognitive Disorders in Type 2 Diabetes: Retrospective Cohort Fin](https://medichelpline.com/clinical-feed/pubmed-42636218.md) (DOI: 10.1371/journal.pone.0356138)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.